Therapies for acute myeloid leukemia: vosaroxin

@inproceedings{Sayar2017TherapiesFA,
  title={Therapies for acute myeloid leukemia: vosaroxin},
  author={Hamid Sayar and Parvaneh Bashardoust},
  booktitle={OncoTargets and therapy},
  year={2017}
}
Vosaroxin, a quinolone-derivative chemotherapeutic agent, was considered a promising drug for the treatment of acute myeloid leukemia (AML). Early-stage clinical trials with this agent led to a large randomized double-blind placebo-controlled study of vosaroxin in combination with intermediate-dose cytarabine for the treatment of relapsed or refractory AML. The study demonstrated better complete remission rates with vosaroxin, but there was no statistically significant overall survival benefit… CONTINUE READING